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From the Editor
What is T.A.P.E.S. ?
TAPES, the Center of Excellence for Technology Assessment and PharmacoEconomic
Services, was created in order to help pharmaceutical and biotechnology companies
assess economic value in a changing health care market place. TAPES is a non-profit
organization funded by a grant from the Ben Franklin Partnership (BFP), an agency
designated by the State of Pennsylvania to provide assistance to local
pharmaceutical and biotechnology firms.
TAPES is a cooperative venture between the Department of Health Policy at Thomas
Jefferson University (TJU), and the Institute for Pharmaceutical Economics at the
Philadelphia College of Pharmacy and Science (PCPS). I serve as the Director of
TAPES, while Dr. Gary Erwin, the Vice President of the Department of Professional
Programs at PCPS, is the Co-Director. We have created a structure for TAPES
enabling TJU and PCPS to perform cost-effectiveness studies that help answer the
question "Even though a drug or treatment modality is safe, is it worth doing ?"
The primary goal of TAPES is to help biotechnology manufacturers conduct outcomes
assessments for both new and established products. By conducting these studies,
TAPES gives local companies the tools they need in order to prove that their products
are not only safe, but also cost-effective.
Creating new pharmaceutical and biotechnological products is not as easy as it used
to be. With health care reform looming like a veritable Sword of Damocles over the
heads of drug and biotechnology companies, consumers and payers are demanding
that in this era of accountability, cost-effectiveness should apply not only to
clinicians, but to product makers as well.
Technology Assessment is a burgeoning field. Many observers believe that there may
be too much expensive technology in today's medicine. The burden of proof as to the
worth of new innovations now rests with the companies that produce them. For the
giants of the industry, this task is daunting, but not impossible; for smaller firms it
can be an overwhelming obstacle that, if not surmounted, could eventually lead to
their elimination from the market place.
The Philadelphia area is home to many such small firms. The Technology Council of
Greater Philadelphia has 400 member companies-Route 202 alone, the famed
"Medical Mile," is home to 30 biotechnology and medical start up firms. The State of
Pennsylvania has demonstrated its commitment to these businesses by funding
TAPES through the auspices of the Ben Franklin Partnership. TAPES provides its
research consulting expertise to members of the Ben Franklin Partnership for
relatively small fees as well as providing a host of other services, including:
individual training sessions, courses in clinical trials and outcomes research, and
periodic conferences.
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One conference sponsored by TAPES and BFP entitled "Developing Health Care
Products for Managed Care Purchasers," took place at Jefferson this past summer.
Over 80 representatives of purchaser, provider, payer, and product groups attended
in order to better understand the changing rules for developing biotechnology
devices and pharmaceutical products in the context of managed care. Speakers
focused on how outcomes research will play a major part in acceptance of and
reimbursement for these products through a series of talks ranging from "The Role of
Outcomes and Economic Research in Product Development," by Nelda Johnson,
PharmD (TJU), to "Your Medical Device: Getting Started with the FDA," by Robert
Mosenkis, President of CITECH, and "How Do Third Party Payers Decide Whether You
Will Be Paid," by Jeffrey Lerner, Ph.D. (ECRI).
The TAPES Center provides an invaluable service to local and national companies. In
studying technology assessment, everyone wins. Companies market more sensible
products, consumers get the most "bang for their buck," and payers get the sense
that what they are paying for is worthwhile.
I appreciate the great teamwork of Gary Erwin and the support he receives from Dr.
Philip Gerbino, the Dean of PCPS. The future of TAPES is exciting, and I am looking
forward to continuing the Jefferson tradition of a productive and beneficial
relationship with PCPS. As always, I encourage members of the Jefferson community
to contact me at extension 6969, or send me a letter sharing your thoughts.

- David B. Nash
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